Kenya has intensified its commitment to Universal Health Coverage (UHC) under the Taifa Care initiative by significantly investing in the health workforce and expanding partnerships with the private sector. These measures aim to strengthen the delivery of quality healthcare services and ensure affordable, accessible care across the country.
To enhance the sustainability of the healthcare workforce, substantial budgetary allocations have been made to support both current personnel and future health professionals. A total of KES 6.2 billion has been earmarked for contract health workers under the UHC framework. Additionally, KES 1.75 billion is dedicated to settling arrears and implementing Return-to-Work Formula (RTWF) agreements, signaling the government’s resolve to honor its obligations and improve labor relations in the health sector.
Further strengthening the pipeline of healthcare professionals, the Ministry has allocated KES 4.2 billion for the deployment of new interns, including doctors, pharmacists, and clinical officers. These interns will bolster service delivery across various health facilities, particularly in underserved areas. Another KES 3.2 billion has been set aside to facilitate the training and provide stipends for Community Health Promoters, who play a crucial role in preventive and primary healthcare at the grassroots level.
The government has also invested KES 13 billion in Primary Healthcare services, with a targeted KES 8 billion directed towards Emergency, Chronic, and Critical Care. These investments are designed to enhance the resilience and responsiveness of the health system, especially in managing non-communicable diseases and urgent medical situations.
In a strategic move to boost healthcare access and affordability, the Ministry is deepening collaborations with key private sector players. Notably, Aga Khan University Hospital and The Nairobi Hospital are now delivering oncology and renal care services including kidney transplants under the Social Health Authority (SHA) tariff, ensuring patients incur no out-of-pocket costs.
Moreover, a public-private partnership with Roche Pharmaceuticals has yielded a significant cost reduction in the price of Herceptin, a critical breast cancer treatment. The price has dropped from KES 120,000 to KES 40,000, making it substantially more affordable for patients in need.
These developments underscore the government’s proactive stance in improving healthcare outcomes by addressing human resource gaps and leveraging partnerships to lower treatment costs. The coordinated efforts between government departments, state agencies, and private institutions reflect a comprehensive approach to achieving equitable healthcare for all Kenyans.
